Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1

NCT01639326 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

96

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Irinotecan high doses
DRUG: Irinotecan standard doses

Sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau